Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, lupus nephritis, and rapid whole blood process. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California. Show more

Location: 5980 Horton Street, Emeryville, CA, 94608, United States | Website: https://kyvernatx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

160.9M

52 Wk Range

$1.78 - $7.85

Previous Close

$3.72

Open

$3.72

Volume

225,702

Day Range

$3.56 - $3.78

Enterprise Value

-45.32M

Cash

211.7M

Avg Qtr Burn

-35.35M

Insider Ownership

12.03%

Institutional Own.

62.34%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.